Skip Navigation

Cardiovascular Research 1995 29(6):856-861; doi:10.1016/S0008-6363(96)88623-8
© 1995 by European Society of Cardiology
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nishikimi, T.
Right arrow Articles by Takeda, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishikimi, T.
Right arrow Articles by Takeda, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1995, European Society of Cardiology

An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat

Toshio Nishikimi*, Hiroyuki Yamagishi, Kazuhide Takeuchi and Tadanao Takeda

First Department of Internal Medicine, Osaka City University Medical School, Osaka, Japan

* Correspondence to Dr Nishikimi, at Division of Hypertension and Nephrology, National Cardiovascular Centre, 5-7-1, Fujishiro-dai, Suita, Osaka 565, Japan.

Objective: The aims were (1) to investigate the effect of hypertension on left ventricular dilatation and haemodynamic alterations following acute myocardial infarction in spontaneously hypertensive rats (SHR) and normotensive rats (WKY); (2) to compare haemodynamic indices between the two groups; (3) to assess whether the angiotensin II type 1 receptor antagonist (AIIA), TCV-116, prevented left ventricular dilatation after myocardial infarction; and (4) to compare the effect of AHA with that of the angiotensin converting enzyme (ACE) inhibitor, delapril. Methods: Myocardial infarction was produced in SHR and WKY by coronary artery ligation. Haemodynamic measurements were obtained three weeks later in rats that had been treated from the next day after the operation for three weeks with TCV-116 (1 mg·kg–1·d–1) or delapril (1 g·litre–1 in drinking water), and in untreated controls. Results: After myocardial infarction, left ventricular systolic pressure, mean arterial pressure, left ventricular end diastolic volume index (LVEDVI), right ventricular weight, and left ventricular weight were greater in SHR than in normotensive rats. Right ventricular weight, left ventricular end diastolic pressure, and LVEDVI correlated positively with infarct size in both SHR and WKY and these slopes were steeper in SHR than in WKY (P < 0.05). TCV-116 and delapril each significantly attenuated the increases in left ventricular end diastolic pressure, left ventricular weight, right ventricular weight, and LVEDVI following myocardial infarction in both in WKY and SHR, and shifted pressure-volume curve significantly to the left. Conclusions: Hypertension accelerates left ventricular dilatation and haemodynamic alterations following myocardial infarction in rats. These effects are attenuated by an angiotensin II type 1 receptor antagonist as well as by an ACE inhibitor.

KEYWORDS myocardial infarction; spontaneously hypertensive rat (SHR); normotensive rat (WKY); left ventricular dilatation; angiotensin II type 1 receptor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. R. Norton, D. G. A. Veliotes, O. Osadchii, A. J. Woodiwiss, and D. P. Thomas
Susceptibility to systolic dysfunction in the myocardium from chronically infarcted spontaneously hypertensive rats
Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H372 - H378.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
P. A Meredith and J. Ostergren
Review: From Hypertension to Heart Failure -- Are There Better Primary Prevention Strategies?
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2006; 7(2): 64 - 73.
[Abstract] [PDF]


Home page
Eur J Heart FailHome page
U. Seeland, I. Kouchi, O. Zolk, F. Jockenhovel, G. Itter, W. Linz, and M. Bohm
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats
Eur J Heart Fail, June 1, 2003; 5(3): 241 - 246.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
R. Schulz and G. Heusch
Review: AT 1-receptor blockade in experimental myocardial ischaemia/reperfusion
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S136 - S140.
[PDF]


Home page
Cardiovasc ResHome page
N. R. Bastien, A.-V. Juneau, J. Ouellette, and C. Lambert
Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival
Cardiovasc Res, July 1, 1999; 43(1): 77 - 85.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
R. S. Vasan and D. Levy
The Role of Hypertension in the Pathogenesis of Heart Failure: A Clinical Mechanistic Overview
Arch Intern Med, September 9, 1996; 156(16): 1789 - 1796.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.